Muscle News and Research

RSS

STSI receives NIH grant to conduct heart-based research

Researchers looking to find a root cause for heart attacks and coronary artery disease will soon begin using a novel investigative approach that borders on science fiction as they work toward the holy grail of American medicine: preventing the nation's No. 1 killer.

2 Jul 2011

Resveratrol may prevent negative effects of spaceflight and sedentary lifestyles

As strange as it sounds, a new research study published in the FASEB Journal (http://www.fasebj.org), suggests that the "healthy" ingredient in red wine, resveratrol, may prevent the negative effects that spaceflight and sedentary lifestyles have on people.

1 Jul 2011

Lantheus commences flurpiridaz F 18 PET MPI Phase 3 trial for detection of coronary artery disease

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of the first of two Phase 3 clinical trials to assess myocardial perfusion using Positron Emission Tomography (PET) imaging with flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD).

1 Jul 2011

Genetic variation associated with increased risk of sudden cardiac arrest

A study by a global consortium of physician-scientists has identified a genetic variation that may predispose people to double the risk of having a sudden cardiac arrest, a disorder that gives little warning and is fatal in about 95 percent of cases.

1 Jul 2011

Chiropractors report high number of back-related injuries during summer moving period

Each year, chiropractors notice a recrudescence of patients that come for a consultation during the summer moving period. Not surprising when we know that many people, eager and tired, hasten to get everything done rapidly without worrying about their muscles and their back. That explains why herniated discs, lumbar pain and muscle soreness are so common during this time of year. How can we avoid this?

30 Jun 2011

New classification for assessing functional status and disability in patients with osteoporosis

A new study brings the experience of physical therapists to a developing "Core Set" of criteria to guide evaluation and treatment for patients with osteoporosis, reports the April/June issue of the Journal of Geriatric Physical Therapy, official journal of the Section on Geriatrics of the American Physical Therapy Association.

30 Jun 2011

Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD

Forest Laboratories, Inc. and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of COPD.

30 Jun 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

Most cases of facial nerve paralysis in children can be treated successfully

A half-paralyzed face with a motionless, drooping side can be alarming at any age, but when it occurs in a child it can be especially devastating.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Nine-year-old recovers with experimental heart pump

Nine-year-old Greer Underwood was healthy until February 2011. What seemingly began as sinusitis on a Tuesday became almost fatal by the weekend when her heart began to fail. Now, after a historic series of events at the University of Alabama at Birmingham, she's the only child in the country to have used the experimental heart pump, Heartware, as a bridge to transplant.

28 Jun 2011

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

HIV drug linked to accelerated and early aging

New research published this Sunday reveals that a class of generic AIDS drugs often used to treat HIV in Africa and other poor regions can cause premature aging and lead to age-related illnesses such as heart disease and dementia.

27 Jun 2011

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain.

27 Jun 2011

Problems of unrecognized alcohol misuse among the elderly

The Royal College of Psychiatrists of London has published a report related primarily to problems of unrecognized alcohol misuse among the elderly. The report provides guidelines for psychiatrists and family physicians on how to find and how to treat elderly people with misuse of alcohol and drugs.

27 Jun 2011

Redefinition of cardiac hypertrophy term needed

The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

New guide indicates when and how genetic testing is useful for inherited cardiac conditions

While genetic inheritance is known to play a role in the multifactorial development of most diseases of the heart, there are also a number of clearly diagnosed cardiac conditions which owe their development to quite specific genetic abnormalities. When these genetic disorders affect the integrity of the heart's muscle they are known as a "cardiomyopathy"; when the disorder affects the heart's "excitability", it is known as a "channelopathy".

27 Jun 2011

Muscle News and Research

STSI receives NIH grant to conduct heart-based research

Resveratrol may prevent negative effects of spaceflight and sedentary lifestyles

Lantheus commences flurpiridaz F 18 PET MPI Phase 3 trial for detection of coronary artery disease

Genetic variation associated with increased risk of sudden cardiac arrest

Chiropractors report high number of back-related injuries during summer moving period

New classification for assessing functional status and disability in patients with osteoporosis

Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Most cases of facial nerve paralysis in children can be treated successfully

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Prototype small molecule drugs could suppress hepatitis C

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Nine-year-old recovers with experimental heart pump

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

HIV drug linked to accelerated and early aging

Cardium to purchase Transdel's business assets

Problems of unrecognized alcohol misuse among the elderly

Redefinition of cardiac hypertrophy term needed

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

New guide indicates when and how genetic testing is useful for inherited cardiac conditions

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News